Clinical trial · Interventional
Exercise to Boost Immunity in Advanced Cancer
Exercise to Boost Immunity in Advanced Cancer: Feasibility of Combined Aerobic Exercise and Resistance Training for Patients with Advanced Mesothelioma and Pancreatic Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The trial is a prospective feasibility trial conducted in Sheffield. Recruitment will include twenty patients receiving first line palliative immunotherapy for advanced, unresectable or metastatic mesothelioma and patients receiving first line systemic anti-cancer treatment for pancreatic cancer. Patients will attend the AWRC for a supervised exercise session once a week to include aerobic exercise along with an unsupervised weekly exercise session for 3 months. Blood samples will be collected at baseline and then monthly for 3 months, pre and post the supervised exercise session. Cytokine, myokine and immune cell concentration will be analysed using cytokine bead-based multiplex immune assays and RNA-seq to full profile changes in gene and protein expression
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Mesothelioma; Lung | — | UNRESOLVED | — |
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Exercise | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Intervention
- description
- The exercise programme will include one weekly supervised exercise sessions and one weekly unsupervised exercise session. The frequency will be twice weekly, one supervised and one unsupervised session a week for 12 weeks. The exercises will be of moderate intensity aerobic interval exercise (performing at 60% maximum heart rate) combined with 1-3 sets of 6-12 Repetition Maximum (RM) resistance training. The type of exercise will be aerobic interval exercise (cycling) and Resistance training (3 exercises: chest press, biceps, and leg curl) The timing will be 4 x 4-minute cycling at 60%, max HR with 3 minutes active recovery. 3 sets with 2 minutes per set - around 20 minutes resistance training
- interventionNames
- Other: Exercise
Primary outcomes (1)
- measure
- Primary Outcome Measure
- timeFrame
- completion of the 12-week exercise intervention
- description
- Adherence rate: The ratio of the number of exercise sessions performed to the number of exercise sessions planned.
Secondary outcomes (7)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients about to start or who are undergoing first line palliative immunotherapy for advanced, unresectable, or metastatic mesothelioma or patients about to start or who are undergoing first line palliative chemotherapy for advanced, unresectable, or metastatic pancreatic cancer. * Age over 18 years old * Histological or cytological diagnosis of mesothelioma or pancreatic cancer. * ECOG Performance status 0-1 (to be assessed by clinician) * Ability to provide informed consent Exclusion Criteria: * Prior treatment with systemic anti-cancer treatment * More than one primary cancer * Uncontrolled brain or bone metastases * Patients who have progressed on first line palliative immunotherapy for advanced, unresectable, or metastatic mesothelioma. * Patients who have progressed on first line palliative chemotherapy for advanced, unresectable, or metastatic pancreatic cancer. * Patients with active co-morbidities that would prevent or limit their participation in the exercise intervention * Age below 18 years old * No histological or cytological diagnosis of mesothelioma or pancreatic cancer. * ECOG Performance status of 2 or more * Unable to provide informed consent
References
Publications (0)
Data not yet available